Literature DB >> 28643088

Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.

Vitaly A Kushnir1,2, David B Seifer3, David H Barad4,5, Aritro Sen4,6, Norbert Gleicher4,5,7,8.   

Abstract

Members of the transforming growth factor-beta (TGF-beta) superfamily are key regulators of various physiological processes. Anti-Müllerian hormone (AMH) which is also commonly known as Müllerian-inhibiting substance (MIS) is a member of the TGF-beta superfamily and an important regulator of reproductive organ differentiation and ovarian follicular development. While AMH has been used for diagnostic purposes as a biomarker for over 15 years, new potential therapeutic applications of recombinant human AMH analogues are now emerging as pharmacologic agents in reproductive medicine. Therapeutic uses of AMH in gonadal tissue may provide a unique opportunity to address a broad range of reproductive themes, like contraception, ovulation induction, onset of menopause, and fertility preservation, as well as specific disease conditions, such as polycystic ovarian syndrome (PCOS) and cancers of the reproductive tract. This review explores the most promising therapeutic applications for a novel class of drugs known as AMH analogues with agonist and antagonist functions.

Entities:  

Keywords:  AMH agonist; AMH analogues; AMH antagonist; Anti-Müllerian hormone; Contraception; Endometrial cancer; Fertility preservation; Fertility treatment; Menopause; Müllerian inhibiting substance; Ovarian cancer; Ovulation induction; Polycystic ovarian syndrome

Mesh：

Substances：

Year:  2017        PMID： 28643088      PMCID： PMC5581791          DOI： 10.1007/s10815-017-0977-4

Source DB:  PubMed          Journal:  J Assist Reprod Genet        ISSN： 1058-0468            Impact factor:   3.412


  90 in total

Review 1.  Optimizing outcomes from ovarian tissue cryopreservation and transplantation; activation versus preservation.

Authors:  Dror Meirow; Hadassa Roness; Stine Gry Kristensen; Claus Yding Andersen
Journal:  Hum Reprod       Date:  2015-09-06       Impact factor: 6.918

2.  Is polycystic ovary syndrome an exception for reproductive aging?

Authors:  Fahimeh Ramezani Tehrani; Masoud Solaymani-Dodaran; Mehdi Hedayati; Fereidoun Azizi
Journal:  Hum Reprod       Date:  2010-04-30       Impact factor: 6.918

3.  Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.

Authors:  Dorry L Segev; Yasunori Hoshiya; Makiko Hoshiya; Trinh T Tran; Jennifer L Carey; Antonia E Stephen; David T MacLaughlin; Patricia K Donahoe; Shyamala Maheswaran
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

4.  Mullerian-inhibiting substance in women with polycystic ovary syndrome: relationship with hormonal and metabolic characteristics.

Authors:  Antonio La Marca; Raoul Orvieto; Simone Giulini; Valerio Maria Jasonni; Annibale Volpe; Vincenzo De Leo
Journal:  Fertil Steril       Date:  2004-10       Impact factor: 7.329

5.  Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels.

Authors:  Athanasia Piouka; Dimitrios Farmakiotis; Ilias Katsikis; Djuro Macut; Spiros Gerou; Dimitrios Panidis
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-28       Impact factor: 4.310

6.  Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.

Authors:  Jamie N Bakkum-Gamez; Giovanni Aletti; Kriste A Lewis; Gary L Keeney; Bijoy M Thomas; Isabelle Navarro-Teulon; William A Cliby
Journal:  Gynecol Oncol       Date:  2007-11-07       Impact factor: 5.482

Review 7.  Targeting the TGFβ signalling pathway in disease.

Authors:  Rosemary J Akhurst; Akiko Hata
Journal:  Nat Rev Drug Discov       Date:  2012-09-24       Impact factor: 84.694

8.  Microbial factories for recombinant pharmaceuticals.

Authors:  Neus Ferrer-Miralles; Joan Domingo-Espín; José Luis Corchero; Esther Vázquez; Antonio Villaverde
Journal:  Microb Cell Fact       Date:  2009-03-24       Impact factor: 5.328

9.  Anti-mullerian hormone is expressed by endometriosis tissues and induces cell cycle arrest and apoptosis in endometriosis cells.

Authors:  Pietro G Signorile; Francesca Petraglia; Alfonso Baldi
Journal:  J Exp Clin Cancer Res       Date:  2014-05-29

10.  The importance of adrenal hypoandrogenism in infertile women with low functional ovarian reserve: a case study of associated adrenal insufficiency.

Authors:  Norbert Gleicher; Vitaly A Kushnir; Andrea Weghofer; David H Barad
Journal:  Reprod Biol Endocrinol       Date:  2016-04-26       Impact factor: 5.211
View more
  12 in total

1.  Oocyte-Derived Factors (GDF9 and BMP15) and FSH Regulate AMH Expression Via Modulation of H3K27AC in Granulosa Cells.

Authors:  Sambit Roy; Divya Gandra; Christina Seger; Anindita Biswas; Vitaly A Kushnir; Norbert Gleicher; T Rajendra Kumar; Aritro Sen
Journal:  Endocrinology       Date:  2018-09-01       Impact factor: 4.736

2.  Effect of In Vitro Maturation of Human Oocytes Obtained After Controlled Ovarian Hormonal Stimulation on the Expression of Development- and Zona Pellucida-Related Genes and Their Interactions.

Authors:  Jure Bedenk; Tadeja Režen; Nina Jančar; Ksenija Geršak; Irma Virant Klun
Journal:  Reprod Sci       Date:  2022-08-01       Impact factor: 2.924

3.  Anti-Müllerian hormone treatment enhances oocyte quality, embryonic development and live birth rate†.

Authors:  Niharika Sinha; Chad S Driscoll; Wenjie Qi; Binbin Huang; Sambit Roy; Jason G Knott; Jianrong Wang; Aritro Sen
Journal:  Biol Reprod       Date:  2022-09-12       Impact factor: 4.161

Review 4.  The role of anti-Müllerian hormone (AMH) in ovarian disease and infertility.

Authors:  Jure Bedenk; Eda Vrtačnik-Bokal; Irma Virant-Klun
Journal:  J Assist Reprod Genet       Date:  2019-11-21       Impact factor: 3.412

5.  Association of Anti-Mullerian Hormone with C-Reactive Protein in Men.

Authors:  Dinesh Kadariya; Nargiza Kurbanova; Rehan Qayyum
Journal:  Sci Rep       Date:  2019-09-11       Impact factor: 4.379

6.  Evaluation of expression and serum concentration of anti-Mullerian hormone as a follicle growth marker following consumption of fennel and flaxseed extract in first-generation mice pups.

Authors:  Fahimeh Pourjafari; Tahereh Haghpanah; Fariba Sharififar; Seyed Noreddin Nematollahi-Mahani; Ali Afgar; Massood Ezzatabadipour
Journal:  BMC Complement Med Ther       Date:  2021-03-12

7.  Recombinant anti-Müllerian hormone in the maturation medium improves the in vitro maturation of human immature (GV) oocytes after controlled ovarian hormonal stimulation.

Authors:  Jure Bedenk; Tadeja Režen; Taja Železnik Ramuta; Nina Jančar; Eda Vrtačnik Bokal; Ksenija Geršak; Irma Virant Klun
Journal:  Reprod Biol Endocrinol       Date:  2022-01-24       Impact factor: 5.211

8.  Clinical Utility of Anti-Mullerian Hormone in Pediatrics.

Authors:  Roopa Kanakatti Shankar; Tazim Dowlut-McElroy; Andrew Dauber; Veronica Gomez-Lobo
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 5.958

Review 9.  Expected advances in human fertility treatments and their likely translational consequences.

Authors:  Norbert Gleicher
Journal:  J Transl Med       Date:  2018-06-04       Impact factor: 5.531

Review 10.  Current and Future Perspectives for Improving Ovarian Tissue Cryopreservation and Transplantation Outcomes for Cancer Patients.

Authors:  Sanghoon Lee; Sinan Ozkavukcu; Seung-Yup Ku
Journal:  Reprod Sci       Date:  2021-03-31       Impact factor: 3.060
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.